A CR-UK phase I dose escalation study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Buparlisib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Planned End Date changed from 1 Mar 2017 to 31 Mar 2018.